Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that has been withdrawn from the market due to potentially serious side effects. It was approved for use in Europe and other countries, but never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It has also been shown to be a μ-opioid receptor antagonist (possibly the contributing factor in its reported dysphoric qualities). Its main effect is reduction in appetite.

CAS：158681-13-1
中文别名：利莫那班盐酸盐;5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-N-(1-哌啶基)-1H-吡唑-3-甲酰胺盐酸盐;N-(哌啶-1-基)-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-甲酰胺盐酸盐;
英文别名：5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide,hydrochloride;Rimonabant hydrochloride;
分子式：C22H22Cl4N4O
分子量：500.248
精确质量：498.055
Psa：50.16
Logp：7.0694

UNII：HL0V2LQZ09

外观与性状：灰白色至白色结晶粉末
沸点：627.6ºC at 760 mmHg
熔点：230-240ºC
闪点：333.3ºC

用途
主要用于减肥、戒烟、高血压、血脂异常和2型糖尿病及代谢综合症（心脑血管疾病主要风险因素典型并发症）。